ReviewNature reviews. Neurology2018
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.
Review in Nature reviews. Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 143 citations in OpenAlex.
- Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.European journal of neurology · 2023Trial
- Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.Journal of neurology, neurosurgery, and psychiatry · 2021Trial
- Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.Brain : a journal of neurology · 2026Article
- Eyes closed single-leg stance test detects subtle sensorimotor decline in early multiple sclerosis.Scientific reports · 2026Article
- Accelerometry-derived activity fragmentation as a predictor of brain atrophy and disability progression in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.Neurology · 2026Article
- Multiple sclerosis risk stratification and healthcare cost prediction using machine learning.Communications medicine · 2025Article
- The importance of patient-reported outcomes: A call for their integration in the routine care of patients with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Review
- Plasma Neurofilament Light Chain Is Associated with Cognitive Functions but Not Patient-Reported Outcomes in Multiple Sclerosis.Neurology international · 2025Article
- Short-term changes in objectively measured activity predict brain atrophy and disability progression in multiple sclerosis.medRxiv : the preprint server for health sciences · 2025Article
- Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis.IBRO neuroscience reports · 2025Review
- The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study.The Lancet regional health. Europe · 2025Article
- Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.Neurology · 2025Observational
- Article
- Evaluation of Disease Modifying Therapies and Prognostic Factors Affecting Multiple Sclerosis Progression in a Local Centre of Hong Kong.Pragmatic and observational research · 2025Article
- Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Investigating cortical hypoxia in multiple sclerosis via time-domain near-infrared spectroscopy.Annals of clinical and translational neurology · 2024Article
- Multiple sclerosis: emerging epidemiological trends and redefining the clinical course.The Lancet regional health. Europe · 2024Review
- Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Review
- Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.Journal of neurology · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing numbers of drugs are being developed for the treatment of multiple sclerosis (MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in clinical trials and for monitoring responses to disease-modifying drugs in individual patients. Most outcomes used in trial and clinical settings reflect either clinical or neuroimaging aspects of MS (such as relapse and accrual of disability or the presence of visible inflammation and brain tissue loss, respectively). However, most measures employed in clinical trials to assess treatment effects are not used in routine practice. In clinical trials, the appropriate choice of outcome measures is crucial because the results determine whether a drug is considered effective and therefore worthy of further development; in the clinic, outcome measures can guide treatment decisions, such as choosing a first-line disease-modifying drug or escalating to second-line treatment. This Review discusses clinical, neuroimaging and composite outcome measures for MS, including patient-reported outcome measures, used in both trials and the clinical setting. Its aim is to help clinicians and researchers navigate through the multiple options encountered when choosing an outcome measure. Barriers and limitations that need to be overcome to translate trial outcome measures into the clinical setting are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.